What are the verified pros and cons of a QC Kinetix franchise?
Data basis. The legal franchisor is QC Franchise Group LLC. The FDD was issued April 30, 2026 and covers the Standard Model, Express Model, and discretionary Development Agreement for additional Standard units. This review uses FDD Items 1, 3–8, 10–12, 15–17, and 19–22.
The contract review includes the Franchise Agreement, Individual Guaranty, Distributor Agreement, Business Associate Agreement, state addenda, and Development Agreement. Item 19 covers the 2025 calendar year; Item 20 covers 2023–2025. Official pages were checked July 31, 2026, but the FDD and signed agreements control contractual obligations.
Public context: official QC Kinetix franchise site, official consumer-brand overview, and the FTC consumer guide to buying a franchise.
Which QC Kinetix features reduce execution ambiguity, and what do they require in return?
The material decision factors are dual-edged. Each verified feature below can improve operating clarity for one buyer profile while increasing cost, dependency, workload, or contractual exposure for another.
Standard Model versus Express Model
Verified fact: The FDD offers a 1,700–2,500-square-foot Standard Model and an Express Model inside an existing healthcare, medical, or wellness clinic using one or two treatment rooms.
Source: 2026 FDD, Item 1, pp. 10–12; Item 7, pp. 23–32. The official franchise process also identifies both current investment ranges.
QCK University and role-based training
Verified fact: Owners University, provider, medical-assistant, front-desk, and sales training are disclosed; the initial curriculum totals 64 classroom and 40 on-the-job hours, with additional role-specific requirements.
Source: 2026 FDD, Item 11, pp. 38–49; Franchise Agreement §16. The official franchise process describes current launch support, but its stated six-month one-on-one support should be confirmed as a written commitment.
Full-time supervision and clinical accountability
Verified fact: The Franchise Agreement requires direct, day-to-day, full-time supervision by the franchisee or an approved trained manager, while the franchisee bears responsibility for provider licensing, credentialing, and clinical oversight.
Source: 2026 FDD, Item 11, pp. 47–48; Item 15, p. 54; Franchise Agreement §8.14. The official owner profile likewise emphasizes hands-on operators and existing clinic owners.
Required suppliers, medical kits, and technology
Verified fact: QC Kinetix may designate itself, affiliates, or approved vendors for medical kits, marketing, card processing, software, equipment, and supplies; required-purchase revenue was 39.3% of franchisor revenue in 2025.
Source: 2026 FDD, Item 8, pp. 33–36; Item 6, pp. 17–23; Franchise Agreement §§8.4 and 8.12.
Protected territory with reserved channels
Verified fact: Each unit receives a DMA-based protected territory or, typically for Express, a seven-mile radius, but the FDD says it is not exclusive and reserves internet and multi-territory accounts.
Source: 2026 FDD, Item 12, pp. 49–51; Franchise Agreement §§3.1–3.5. The official franchise FAQ uses “protected” territory language; the FDD’s nonexclusive definition controls.
Central marketing, call center, and recurring minimums
Verified fact: The royalty is 8% of weekly Gross Revenues, with $1,000 monthly minimums in months three through five and $1,500 from month six; local marketing can reach $40,000.
Source: 2026 FDD, Item 6, pp. 17–23; Item 11, pp. 40–43; Franchise Agreement §§6.1–6.6.
Ten-year term and constrained exit
Verified fact: The initial term is ten years with two five-year renewal options; the franchisee has no contractual termination right, and early termination can trigger minimum royalties, call-center fees, and technology fees through expiration.
Source: 2026 FDD, Item 17, pp. 55–61; Item 6, pp. 22–23; Franchise Agreement §§4, 15, and 18–21; Individual Guaranty. State addenda can modify enforceability.
How far does the protected territory actually extend?
A buyer receives a defined geographic area, not control of every channel that can reach that area. This distinction matters most to buyers whose patient-acquisition plan depends on local digital marketing, regional employers, or accounts operating across several territories.
Interpretation: “Protected” is narrower than “exclusive.” The buyer should map every reserved channel against the proposed DMA, referral strategy, and digital customer-acquisition plan.
Source: 2026 FDD, Item 12, pp. 49–51; Franchise Agreement §3 and Schedule 3.
What does Item 19 establish, and what remains uncertain?
Item 19 provides a 2025 income-statement presentation for 39 franchised outlets that operated for all twelve months. That is more decision-useful than no financial performance representation, but it covers only 39% of the 100 eligible full-year franchised outlets, excludes company-owned outlets, and was not audited.
Interpretation: The disclosed average, median, minimum, and maximum describe the 39 reporting outlets, not every eligible QC Kinetix franchise or a guaranteed result for either model.
Source: 2026 FDD, Item 19, pp. 61–62. Formula: 39 reporting outlets ÷ 100 eligible outlets = 39%; 61 ÷ 100 = 61%.
Item 19 does not disclose why 61 eligible outlets lacked complete data, whether Standard and Express results differ, or how the 39 outlets are distributed by market maturity, geography, owner involvement, or local advertising level. Request the written substantiation, the model mix, and a reconciliation to the exact operating plan under review.
What does Item 20 show about the QC Kinetix network?
Year-end franchised outlets increased to 172 in 2023, then declined to 153 in 2024 and 104 in 2025. Company- or affiliate-owned outlets ended those years at 12, 14, and 6. The pattern is a due-diligence signal about system direction, not proof that every departure had the same cause.
Interpretation: Franchised outlets fell 39.5% from year-end 2023 to year-end 2025; 2025 separately reports 6 openings, 32 terminations, 1 reacquisition, and 22 outlets that ceased operations for other reasons.
Source: 2026 FDD, Item 20, Tables 1, 3, and 4, pp. 62–70. Calculation: (104 − 172) ÷ 172 = −39.5%.
Terminations, reacquisitions, transfers, and ceased operations are separate FDD categories and should not be relabeled as identical failures. The material buyer question is why the network contracted and whether the causes apply to the proposed model, market, operator profile, advertising budget, and clinical structure.
The FDD’s special-risk page says the franchisor’s financial condition raises questions about support capacity. Audited notes report 2025 revenue of $25.6 million versus $29.3 million in 2024, cash equivalents of $0.43 million versus $8.46 million, and $7.99 million of long-term debt. These facts do not establish insolvency; they support an accountant’s review of the complete Item 21 statements.
Source: 2026 FDD, special risks, p. 6; Item 21 and Exhibit H, audited financial statements for 2025 and 2024.
What should a buyer verify before signing?
The highest-value questions are model-specific and contract-specific. Written answers should be reconciled to the final FDD, state addenda, Schedule 3 territory map, supplier schedules, and the exact Franchise Agreement presented for signature.
The FTC recommends reviewing the FDD, attached agreements, financial performance substantiation, and current and former franchisee contacts before signing; see the FTC’s FDD review guidance.
Who may align with the model, and who may experience friction?
More aligned under stated conditions
- Existing clinic owner: can evaluate Express using real treatment rooms, staff, lease economics, and clinical governance.
- Hands-on operator: accepts full-time supervision, structured reporting, approved systems, centralized call handling, and role-based training.
- Healthcare-capable team: can manage licensed providers, medical-director oversight, HIPAA, advertising rules, patient financing, and state-specific entity structure.
- Long-horizon buyer: can absorb a ten-year commitment, recurring minimums, system changes, and a constrained transfer or termination path.
More likely to experience friction
- Passive capital investor: conflicts with direct, day-to-day, full-time supervision unless an approved trained manager carries that role.
- Customization-driven physician: may resist approved products, services, pricing parameters, suppliers, advertising, software, and internet controls.
- Low-fixed-cost buyer: may struggle with minimum royalties, call-center and technology fees, medical staffing, insurance, and local advertising requirements.
- Short-horizon buyer: faces transfer approval, fees, release requirements, noncompetition, personal guarantees, and potential liquidated damages.